Rivus Advances in Obesity-Related Heart Failure with Mid-Stage Success of HU6

Mid-Stage Success:
Rivus Pharmaceuticals announced a statistically significant weight reduction in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) in the Phase IIa HuMAIN trial.

Phase III Plans:
Rivus is on track to engage with regulatory authorities and launch a Phase III study for HU6 in obesity-related HFpEF next year.

Muscle-Preserving Mechanism:
HU6 works by raising resting metabolic rate, selectively burning fat without reducing muscle mass, which is crucial for patients with HFpEF.

Broad Potential:
HU6 is also being assessed for metabolic dysfunction-associated steatohepatitis, with enrollment completed in the Phase II M-ACCEL trial and topline results expected in the first half of 2025.

Clinical Data Presentation:
Rivus will present detailed data from the HuMAIN trial at the Heart Failure Society of America Annual Scientific Meeting in September 2024.